{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:13:51Z","timestamp":1648923231570},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"21-22","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00508-010-1483-1","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T01:25:01Z","timestamp":1289438701000},"page":"649-652","source":"Crossref","is-referenced-by-count":0,"title":["Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting"],"prefix":"10.1007","volume":"122","author":[{"given":"Edgar","family":"Petru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Reinthaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Angleitner-Boubenizek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Dirschlmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Medl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stummvoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sevelda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,15]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with carboplatin and paclitaxel for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323\u20139","journal-title":"J Clin Oncol"},{"key":"1483_CR2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A DuBois","year":"2003","unstructured":"DuBois A, L\u00fcck HJ, Meier W, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. JNCI 2003;95:1320\u201330","journal-title":"JNCI"},{"key":"1483_CR3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"T Smith","year":"2006","unstructured":"Smith T, Khatcheressian J, Lyman G, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187\u2013205","journal-title":"J Clin Oncol"},{"key":"1483_CR4","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"B Monk","year":"2010","unstructured":"Monk B, Herzog T, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010;28:3107\u201314","journal-title":"J Clin Oncol"},{"key":"1483_CR5","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-Ovar, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699\u2013707","journal-title":"J Clin Oncol"},{"key":"1483_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1359-6349(09)72053-1","volume":"7","author":"P Vasey","year":"2009","unstructured":"Vasey P, Largiller R, Gropp M, et al. A GCIG randomized phase III study of carboplatin & pegylated liposomal doxorubicin versus carboplatin & paclitaxel: CALYPSO results in partially platinum-sensitive ovarian cancer patients. Eur J Cancer Suppl 2009;7:11 (Abstr 18LBA)","journal-title":"Eur J Cancer Suppl"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1483-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-010-1483-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-010-1483-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:53:23Z","timestamp":1559080403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-010-1483-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":6,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1007\/s00508-010-1483-1","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}